Plasminogen activator inhibitor-1 predicts quantity of hepatic steatosis independent of insulin resistance and body weight

Jeffrey R. Holzberg, Ran Jin, Ngoc Anh Le, Thomas R. Ziegler, Elizabeth M. Brunt, Craig J. Mcclain, Juna V. Konomi, Gavin E. Arteel, Miriam B. Vos

Research output: Contribution to journalArticle

5 Scopus citations


Objective: The aim of the present study was to examine the association between plasminogen activator inhibitor-1 (PAI-1), an acute phase protein strongly associated with cardiovascular disease risk, and adiposity, insulin resistance, and inflammation among overweight and obese children with a wide range of hepatic steatosis. Methods: Plasma PAI-1 levels were measured in a prospectively recruited cohort of 39 overweight or obese children who underwent comprehensive anthropometric assessment and metabolic measurements. Hepatic steatosis was quantified using magnetic resonance spectroscopy and participants were divided into 3 groups based on whether they had normal hepatic steatosis (<5%), low hepatic steatosis (≥5%-10%), and high hepatic steatosis (>10%). Results: Plasma PAI-1 levels significantly increased across the severity of hepatic steatosis in overweight and obese children, and this association was independent of body mass index z score, visceral fat, insulin resistance, and inflammatory markers (P<0.05). Conclusion: Hepatic steatosis in children is positively associated with circulating levels of PAI-1 independent of body mass index, insulin resistance, and inflammatory markers. Further studies are needed to clarify the potential role of PAI-1 as a therapeutic target in pediatric nonalcoholic fatty liver disease.

Original languageEnglish
Pages (from-to)819-823
Number of pages5
JournalJournal of pediatric gastroenterology and nutrition
Issue number6
StatePublished - Jun 1 2016


  • cardiovascular disease risk
  • children
  • insulin resistance
  • nonalcoholic fatty liver disease
  • plasminogen activator inhibitor-1

Fingerprint Dive into the research topics of 'Plasminogen activator inhibitor-1 predicts quantity of hepatic steatosis independent of insulin resistance and body weight'. Together they form a unique fingerprint.

  • Cite this